$DMAC
DiaMedica Therapeutics Inc.

2022 Q3 Form 10-Q Financial Statement

#000143774922019848 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.488M $1.409M $1.562M
YoY Change 37.27% 16.54% 29.09%
% of Gross Profit
Research & Development $1.640M $1.955M $1.974M
YoY Change -29.67% -9.32% -17.96%
% of Gross Profit
Depreciation & Amortization $7.000K $6.000K $6.000K
YoY Change 16.67% 200.0% 0.0%
% of Gross Profit
Operating Expenses $1.640M $1.955M $1.974M
YoY Change -29.67% -9.32% -17.96%
Operating Profit -$3.128M -$3.364M -$3.536M
YoY Change -8.43% -0.03% -2.29%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $76.00K $13.00K $35.00K
YoY Change -381.48% -86.73% 775.0%
Pretax Income -$3.052M -$3.351M -$3.501M
YoY Change -11.36% 2.57% -3.15%
Income Tax $7.000K $7.000K $7.000K
% Of Pretax Income
Net Earnings -$3.059M -$3.358M -$3.508M
YoY Change -11.33% 2.57% -3.15%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.13 -$0.13
Diluted Earnings Per Share -$115.7K -$127.0K -$132.7K
COMMON SHARES
Basic Shares Outstanding 26.44M 26.44M 26.44M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.08M $38.44M $41.03M
YoY Change -25.01% 80.25% 75.13%
Cash & Equivalents $2.771M $3.062M $3.032M
Short-Term Investments $33.31M $35.38M $38.00M
Other Short-Term Assets $331.0K $642.0K $896.0K
YoY Change -1.49% 101.89% 94.78%
Inventory
Prepaid Expenses
Receivables $75.00K $88.00K $168.0K
Other Receivables $0.00 $0.00 $2.000K
Total Short-Term Assets $36.49M $39.17M $42.11M
YoY Change -24.82% 81.11% 74.05%
LONG-TERM ASSETS
Property, Plant & Equipment $110.0K $74.00K $74.00K
YoY Change 57.14% 1.37% -1.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $551.0K $85.00K $100.0K
YoY Change 333.86% -41.38% -37.89%
TOTAL ASSETS
Total Short-Term Assets $36.49M $39.17M $42.11M
Total Long-Term Assets $551.0K $85.00K $100.0K
Total Assets $37.04M $39.26M $42.21M
YoY Change -23.88% 80.3% 73.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $864.0K $624.0K $433.0K
YoY Change 23.61% 161.09% -37.16%
Accrued Expenses $637.0K $894.0K $967.0K
YoY Change -26.02% -21.02% 130.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.000K $7.000K $6.000K
YoY Change 75.0% 40.0% -40.0%
Total Short-Term Liabilities $1.542M $1.536M $1.434M
YoY Change -5.05% 6.67% 21.73%
LONG-TERM LIABILITIES
Long-Term Debt $5.000K $7.000K $9.000K
YoY Change 25.0% 40.0% -10.0%
Other Long-Term Liabilities $415.0K
YoY Change
Total Long-Term Liabilities $420.0K $7.000K $9.000K
YoY Change 10400.0% -56.25% -72.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.542M $1.536M $1.434M
Total Long-Term Liabilities $420.0K $7.000K $9.000K
Total Liabilities $1.962M $1.543M $1.443M
YoY Change 20.52% 5.98% 19.16%
SHAREHOLDERS EQUITY
Retained Earnings -$92.40M -$89.40M -$86.00M
YoY Change 16.52% 17.94% 18.57%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.10M $37.70M $40.77M
YoY Change
Total Liabilities & Shareholders Equity $37.04M $39.26M $42.21M
YoY Change -23.88% 80.3% 73.31%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.059M -$3.358M -$3.508M
YoY Change -11.33% 2.57% -3.15%
Depreciation, Depletion And Amortization $7.000K $6.000K $6.000K
YoY Change 16.67% 200.0% 0.0%
Cash From Operating Activities -$2.361M -$2.496M -$3.900M
YoY Change -22.49% 19.31% -9.58%
INVESTING ACTIVITIES
Capital Expenditures -$43.00K -$6.000K $0.00
YoY Change 2050.0% 100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $2.115M $2.534M $2.214M
YoY Change -116.49% 155.19%
Cash From Investing Activities $2.072M $2.528M $2.214M
YoY Change -116.15% 155.35% -24700.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.000K -2.000K -$1.000K
YoY Change -100.01% -300.0% -100.41%
NET CHANGE
Cash From Operating Activities -2.361M -2.496M -$3.900M
Cash From Investing Activities 2.072M 2.528M $2.214M
Cash From Financing Activities -2.000K -2.000K -$1.000K
Net Change In Cash -291.0K 30.00K -$1.675M
YoY Change -102.08% -102.72% -58.95%
FREE CASH FLOW
Cash From Operating Activities -$2.361M -$2.496M -$3.900M
Capital Expenditures -$43.00K -$6.000K $0.00
Free Cash Flow -$2.318M -$2.490M -$3.900M
YoY Change -23.85% 19.2% -9.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
-0 usd
us-gaap Variable Lease Cost
VariableLeaseCost
26000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
40405000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001401040
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36291
dei Entity Registrant Name
EntityRegistrantName
DIAMEDICA THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Address Line1
EntityAddressAddressLine1
Two Carlson Parkway, Suite 260
dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55447
dei City Area Code
CityAreaCode
763
dei Local Phone Number
LocalPhoneNumber
312-6755
dei Security12b Title
Security12bTitle
Voting common shares, no par value per share
dei Trading Symbol
TradingSymbol
DMAC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26443067
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3062000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4707000 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
35381000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
88000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
130000 usd
CY2022Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
108000 usd
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
113000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
39173000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45439000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42000 usd
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
85000 usd
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
112000 usd
CY2022Q2 us-gaap Assets
Assets
39258000 usd
CY2021Q4 us-gaap Assets
Assets
45551000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
624000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
509000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
894000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
966000 usd
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
7000 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
45000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1536000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1524000 usd
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
7000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3000 usd
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7000 usd
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3000 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26443067
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26443067
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26443067
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
127249000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126576000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-167000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-51000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89367000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82501000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
37715000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44024000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39258000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45551000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1955000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3358000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3274000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3273000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6982000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6897000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26443067
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18786157
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26443067
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18776461
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44024000 usd
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
308000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3508000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
40768000 usd
CY2022Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
365000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-60000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3358000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
37715000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 usd
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
511000 usd
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3622000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
23145000 usd
CY2021Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
446000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3274000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
20318000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6896000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
673000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
957000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-160000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-38000 usd
dmac Noncash Lease Expense
NoncashLeaseExpense
31000 usd
dmac Noncash Lease Expense
NoncashLeaseExpense
28000 usd
us-gaap Depreciation
Depreciation
12000 usd
us-gaap Depreciation
Depreciation
12000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-324000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-5000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-6000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
450000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
250000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
115000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-860000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-106000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
239000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6384000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6402000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
27510000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
26235000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4742000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
980000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
244000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1645000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2228000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
10000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89400000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6900000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6400000 usd
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
38400000 usd
CY2022Q2 dmac Working Capital
WorkingCapital
37600000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
37700000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<i>Concentration of credit risk</i>  Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with two financial institutions. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 usd
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
88000 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
130000 usd
CY2022Q2 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
151000 usd
CY2021Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
191000 usd
CY2022Q2 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
7000 usd
CY2021Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
7000 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
894000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
966000 usd
CY2022Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
108000 usd
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
113000 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
141000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
137000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
67000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
67000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000 usd
CY2022Q2 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
529000 usd
CY2021Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
284000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
207000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
484000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
32000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11000 usd
dmac Stock Issued During Period Shares Exercise Of Common Stock Warrants
StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants
0
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5724410
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3358000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3274000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6866000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6896000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26443067
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18786157
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26443067
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18776461
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
365000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
446000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
673000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
957000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1896600
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.22
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
169000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
837398
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
57813
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
8.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
52187
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.90
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2623998
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.37
CY2022Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2623998
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2022Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.37
CY2022Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1358459
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y3M18D

Files In Submission

Name View Source Status
0001437749-22-019848-index-headers.html Edgar Link pending
0001437749-22-019848-index.html Edgar Link pending
0001437749-22-019848.txt Edgar Link pending
0001437749-22-019848-xbrl.zip Edgar Link pending
dmac-20220630.xsd Edgar Link pending
dmtp20220630_10q.htm Edgar Link pending
ex_405323.htm Edgar Link pending
ex_405324.htm Edgar Link pending
ex_405325.htm Edgar Link pending
ex_405326.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pic1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
dmac-20220630_lab.xml Edgar Link unprocessable
dmac-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dmac-20220630_def.xml Edgar Link unprocessable
dmac-20220630_cal.xml Edgar Link unprocessable
dmtp20220630_10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending